Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT: Semaglutide CV Outcomes in Overweight or Obesity
NCT03574597Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2018
- Primary completion
- Jun 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 42
01
Overview
A Phase 3 trial of semaglutide in Overweight, obesity, sponsored by Novo Nordisk. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT03574597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574597.